BeStock  
Stocks › Biotechnology › MNKD

MannKind MNKD

US equityMarket cap rank #3020Biotechnology
$3.85 −$0.10 (-2.53%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.93 +2.08%
Open$3.90
Prev close$3.95
Day range$3.83 – $4.08
Volume4.18M
Market cap$1.24B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership56.3%-4.05 pts vs. prior quarter
Institutions holding302-7 vs. prior quarter
Insider trades (recent)29 buys / 21 sellsNet buying
Short interest8.15% of floatDays to cover 10.3 · as of 30 Oct 2026
Short-sale volume share24.3%5-day average of daily volume

Short-sale volume as % of daily volume

15%25%35%45%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$4.66M (5 inflow days, 15 outflow days).

Net flow by order size, last 20 sessions

−$3.0MSuper−$1.6MBig−$1.6MMid−$2.9MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 27.4% of shares outstanding.

Largest holders

  • BlackRock10.23%
  • Rubric Capital Management LP5.60%
  • State Street Global Advisors4.69%
  • Vanguard Capital Management, LLC4.40%
  • Geode Capital Management, LLC2.50%
  • Wellington Management Group2.44%
  • Frazier Life Sciences Management, LP2.05%
  • Deep Track Capital, LP1.87%

By investor type

  • Mutual Fund35.58%
  • Hedge Fund10.64%
  • VC/PE Fund3.93%
  • Public Company3.00%
  • Individual/Insider1.85%
  • Family Office/Trust1.61%
  • Private Company0.70%
  • Government Pension Fund0.44%

Reported short interest has fallen from 8.89% to 8.15% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
First Trust Advisors L.P. Mutual Fund 2026/Q3 +1,002,678 0.6%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +998,435 4.4%
BlackRock Mutual Fund 2026/Q3 +786,236 10.2%
Voya Investment Management LLC Mutual Fund 2026/Q3 +524,726 0.2%
FMR Mutual Fund 2026/Q3 +438,827 1.4%
Rubric Capital Management LP Hedge Fund 2026/Q3 +14,379,587 5.6%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +6,000,000 1.9%
Wellington Management Group Mutual Fund 2026/Q3 +4,561,628 2.4%
BlackRock Mutual Fund 2026/Q3 +3,532,225 10.0%
Braidwell LP Hedge Fund 2026/Q3 +3,458,429 1.1%
AQR Capital Management Hedge Fund 2026/Q3 +3,316,723 1.2%
J. Goldman & Co., L.P. Hedge Fund 2026/Q3 +816,589 0.3%
Frazier Life Sciences Management, LP VC/PE Fund 2026/Q3 +700,000 2.1%
180 Wealth Advisors, LLC Family Office/Trust 2026/Q3 +667,648 1.5%
TSP Capital Management Group, LLC Mutual Fund 2026/Q3 +628,700 1.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
24 Sep 2026 Steven Binder Independent Director Automatic Disposition -39,051 $3.29 546,758
9 Sep 2026 Steven Binder Independent Director Automatic Disposition -33,558 $3.81 585,809
6 Aug 2026 Steven Binder Independent Director Automatic Disposition -39,051 $4.06 619,367
16 Jul 2026 David Thomson General Counsel Automatic Disposition -24,109 $4.05 620,804
16 Jul 2026 Steven Binder Independent Director Derivative Exercise and Sale -76,880 $4.09 658,418
14 Jul 2026 David Thomson General Counsel Sale to Issuer -4,636 $4.09 620,804
14 Jul 2026 David Thomson General Counsel Derivative Exercise and Sale -93,790 $4.09 620,804
14 Jul 2026 Stuart Tross Chief People & Workplace Officer Derivative Exercise and Sale -65,808 $4.09 881,392
14 Jul 2026 Stuart Tross Chief People & Workplace Officer Derivative Exercise and Retained +27,982 – 881,392
14 Jul 2026 Michael Castagna Chief Executive Officer Sale to Issuer -12,940 $4.09 2,433,779
14 Jul 2026 Michael Castagna Chief Executive Officer Derivative Exercise and Sale -350,260 $4.09 2,433,779
14 Jul 2026 Steven Binder Independent Director Derivative Exercise and Retained +16,910 – 658,418
14 Jul 2026 Christopher Prentiss Chief Financial Officer Sale to Issuer -22,247 $4.09 95,851
14 Jul 2026 Dominic Marasco President of Endocrine Business Unit Sale to Issuer -3,623 $4.09 46,773
14 Jul 2026 Sanjay Singh Executive Vice President of Technical Operations Derivative Exercise and Sale -46,795 $4.09 253,404
14 Jul 2026 Sanjay Singh Executive Vice President of Technical Operations Derivative Exercise and Retained +23,755 – 253,404
19 May 2026 Ronald Consiglio Independent Director Other Acquisition +10,000 $2.95 132,342
19 May 2026 Ronald Consiglio Independent Director Other Derivative Acquisition +99,337 – 16,556
19 May 2026 Christine Ann Mundkur Independent Director Other Derivative Acquisition +82,781 – 82,781
19 May 2026 Michael Friedman Independent Director Other Derivative Acquisition +82,781 – 82,781

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 26,220,516 8.2% 10.3
15 Oct 2026 25,478,417 7.9% 5.1
30 Sep 2026 26,157,578 8.1% 4.4
15 Sep 2026 29,398,550 9.1% 9.1
31 Aug 2026 26,554,857 8.3% 8.5
14 Aug 2026 28,582,134 8.9% 5.6

Discussion

No comments yet — be the first to weigh in on MNKD.

Sign in to join the discussion.

Scroll to Top